VIRI vs. NRSN, FLGC, TRAW, AKTX, EDSA, RDHL, IMNN, PIRS, KPRX, and ELAB
Should you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include NeuroSense Therapeutics (NRSN), Flora Growth (FLGC), Traws Pharma (TRAW), Akari Therapeutics (AKTX), Edesa Biotech (EDSA), RedHill Biopharma (RDHL), Imunon (IMNN), Pieris Pharmaceuticals (PIRS), Kiora Pharmaceuticals (KPRX), and Elevai Labs (ELAB). These companies are all part of the "pharmaceutical preparations" industry.
NeuroSense Therapeutics (NASDAQ:NRSN) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.
NeuroSense Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500.
NeuroSense Therapeutics' return on equity of -127.42% beat Virios Therapeutics' return on equity.
In the previous week, Virios Therapeutics' average media sentiment score of 0.00 equaled NeuroSense Therapeutics'average media sentiment score.
NeuroSense Therapeutics and Virios Therapeutics both received 2 outperform votes by MarketBeat users. However, 100.00% of users gave NeuroSense Therapeutics an outperform vote while only 66.67% of users gave Virios Therapeutics an outperform vote.
1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Virios Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Virios Therapeutics beats NeuroSense Therapeutics on 7 of the 10 factors compared between the two stocks.
Get Virios Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virios Therapeutics Competitors List
Related Companies and Tools
